Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human IL6ST Antibodies:
anti-Mouse (Murine) IL6ST Antibodies:
anti-Rat (Rattus) IL6ST Antibodies:
Go to our pre-filtered search.
Human Monoclonal IL6ST Primary Antibody for FACS, IP - ABIN1383683
Wijdenes, Heinrich, Müller-Newen, Roche, Gu, Clément, Klein: Interleukin-6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies. in European journal of immunology 1996
Show all 26 Pubmed References
Human Monoclonal IL6ST Primary Antibody for FACS, IP - ABIN1383685
Fourcin, Chevalier, Guillet, Robledo, Froger, Pouplard-Barthelaix, Gascan: gp130 transducing receptor cross-linking is sufficient to induce interleukin-6 type responses. in The Journal of biological chemistry 1996
Show all 24 Pubmed References
Human Monoclonal IL6ST Primary Antibody for FACS - ABIN1383678
Gu, Wijdenes, Zhang, Hallet, Clement, Klein: Anti-gp130 transducer monoclonal antibodies specifically inhibiting ciliary neurotrophic factor, interleukin-6, interleukin-11, leukemia inhibitory factor or oncostatin M. in Journal of immunological methods 1996
Show all 19 Pubmed References
Human Monoclonal IL6ST Primary Antibody for FACS - ABIN1383682
Chevalier, Fourcin, Robledo, Wijdenes, Pouplard-Barthelaix, Gascan: Interleukin-6 family of cytokines induced activation of different functional sites expressed by gp130 transducing protein. in The Journal of biological chemistry 1996
Show all 15 Pubmed References
Mouse (Murine) Monoclonal IL6ST Primary Antibody for CyTOF, FACS - ABIN4899764
Bailey, Huang, Kam, Farzan: Ifitm3 limits the severity of acute influenza in mice. in PLoS pathogens 2012
Show all 6 Pubmed References
Human Monoclonal IL6ST Primary Antibody for FACS - ABIN1383681
Auguste, Guillet, Fourcin, Olivier, Veziers, Pouplard-Barthelaix, Gascan: Signaling of type II oncostatin M receptor. in The Journal of biological chemistry 1997
Show all 5 Pubmed References
Human Monoclonal IL6ST Primary Antibody for FACS - ABIN1383684
Müller-Newen, Köhne, Keul, Hemmann, Müller-Esterl, Wijdenes, Brakenhoff, Hart, Heinrich: Purification and characterization of the soluble interleukin-6 receptor from human plasma and identification of an isoform generated through alternative splicing. in European journal of biochemistry / FEBS 1996
Show all 4 Pubmed References
Mouse (Murine) Monoclonal IL6ST Primary Antibody for FACS - ABIN4896627
Pratama, Srivastava, Williams, Papa, Lee, Dinh, Hutloff, Jordan, Zhao, Casellas, Athanasopoulos, Vinuesa: MicroRNA-146a regulates ICOS-ICOSL signalling to limit accumulation of T follicular helper cells and germinal centres. in Nature communications 2015
Show all 4 Pubmed References
Human Monoclonal IL6ST Primary Antibody for FACS - ABIN1383679
Menetrier-Caux, Thomachot, Alberti, Montmain, Blay: IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. in Cancer research 2001
Show all 3 Pubmed References
Human Monoclonal IL6ST Primary Antibody for FACS - ABIN4897911
Larsen, Hansen, Møller, Madsen, Scheller, Nielsen, Petersen: Sortilin facilitates signaling of ciliary neurotrophic factor and related helical type 1 cytokines targeting the gp130/leukemia inhibitory factor receptor beta heterodimer. in Molecular and cellular biology 2010
Show all 3 Pubmed References
we show by molecular replacement that Arg-112 does not participate in binding of IL-11 to its receptors IL-11R and glycoprotein 130 (gp130). Recombinant IL-11 R112H expressed in E. coli displays a correct four-helix-bundle folding topology, and binds with similar affinity to IL-11R and the IL-11/IL-11R/gp130 complex.
SNP rs10940495 in the gp130 locus was associated with functional outcome at 6 months following spontaneous intracerebral hemorrhage.
Decreased serum LIF levels may be associated with vasculopathy in systemic sclerosis (SSc) and that Fli1 deficiency may contribute to the inhibition of LIF-dependent biological effects on SSc endothelial cells by suppressing the expression of LIF, LIF receptor, and gp130.
gp130 is associated with adverse postoperative clinical outcomes of patients with late-stage non-metastatic gastric cancer.
GP130 signaling is required for tumor cell survival in diverse forms of ALK- anaplastic large cell lymphoma, even in the presence of JAK1 (show JAK1 Antibodies)/STAT3 (show STAT3 Antibodies) mutations.
Data show that tumor suppressor adenomatous polyposis coli (APC (show APC Antibodies)) loss results in up-regulation of IL-6 (show IL6 Antibodies) signal transducer (IL-6ST/gp130), thereby activating YAP (show YAP1 Antibodies) (YY1 (show YY1 Antibodies)-associated) protein (YAP (show YAP1 Antibodies)) which are simultaneously up-regulated in the majority of colorectal cancer (CRC (show CALR Antibodies)).
study focused on IL-6 (show IL6 Antibodies) and activation of its receptors gp80 (show CLU Antibodies) and gp130 in human gingival fibroblasts in order to assess the effects of the commercial acid resins Jet (show FBXL15 Antibodies) Kit, Unifast, and Duralay on control of inflammation
an impaired oxidative stress response in hepatocytes with gp130 gain-of-function mutations, as detected in dysplastic intrahepatic nodules and hepatocellular adenomas, is one of the central oncogenic mechanisms in chronic liver inflammation.
The sgp130, IL-6 (show IL6 Antibodies), and sIL (show PMEL Antibodies)-6R concentrations were statistically significantly elevated in patients with diabetic retinopathy (DR), suggesting a probable contributing role of the IL-6 (show IL6 Antibodies) trans-signaling pathway to the pathophysiology of DR.
This functional mouse model of PMM2-CDG, in vitro assays and identification of the novel gp130 biomarker all shed light on the human disease, and moreover, provide the essential tools to test potential therapeutics for this untreatable disease.
Genetic ablation of APN (show ANPEP Antibodies) expression had no effect on infectability by porcine epidemic diarrhea virus, demonstrating that APN (show ANPEP Antibodies) is not essential for porcine epidemic diarrhea virus cell entry.
pAPN (show ANPEP Antibodies) is not a functional receptor for porcine epidemic diarrhea virus, but promotes the infection of PEDV through its protease activity.
The C-terminal domain of the S1 domain of porcine epidemic diarrhea virus is bound to swine pAPN (show ANPEP Antibodies).
Data indicate that fluorogenic substrates can be successfully used to identify aminopeptidase N (show ANPEP Antibodies) and to measure their activity in cell lysates.
SPC (show SFTPC Antibodies) subdomain of APN (show ANPEP Antibodies) plays a key role in cell entry of PEDV and its expression permits PEDV growth
Porcine epidemic diarrhea virus recognizes protein receptor aminopeptidase N (show ANPEP Antibodies) from pig and human and sugar coreceptor N-acetylneuraminic acid.
These data demonstrate that pAPN (show ANPEP Antibodies), the cellular receptor for porcine epidemic diarrhea virus, mediates polarized virus infection.
It was concluded that the difference in F4 binding to ANPEP (show ANPEP Antibodies) is due to modifications in its carbohydrate moieties.
The region aa 673-722 of the C subunit of porcine aminopeptidase N (show ANPEP Antibodies) is indicated to play a key role in swine transmissible gastroenteritis virus binding.
The binding ability of four truncated porcine aminopeptidase N (show ANPEP Antibodies) proteins to transmissible gastroenteritis virus (TGEV), a porcine coronavirus, was analyzed by ELISA and immunoblotting.
EBI3 can mediate IL-6 trans-signaling in a process that involves gp130
data suggest that the different sgp130 forms are released from cells into their immediate surroundings and appear to form cell-associated gradients to modulate their own susceptibility for IL-6 (show IL6 Antibodies) trans-signaling.
Blocking IL-6 (show IL6 Antibodies) trans-signaling in the CNS abrogates the ability of IL-6 (show IL6 Antibodies) to suppress feeding. Furthermore, gp130 (show LRPPRC Antibodies) expression is enhanced in the paraventricular nucleus of the hypothalamus (PVH) of obese mice, and deletion of gp130 (show LRPPRC Antibodies) in the PVH attenuates the beneficial central IL-6 (show IL6 Antibodies) effects on metabolism
C2C12 myotubes possesses a mechanism for regulating IL-6R and gp130 expression following lipoic acid treatment or heat shock.
Results suggest that the protective role of gp130 (show LRPPRC Antibodies)-dependent STAT3 (show STAT3 Antibodies) activation in experimental colitis involves the expansion and activation of mucosal myeloid-derived suppressor cells.
IL-6/gp130 signalling in the osteoclast is not essential for normal bone resorption in vivo, but maintains both trabecular and periosteal bone formation in male mice by promoting osteoblast activity through the stimulation of osteoclast-derived coupling factors and osteotransmitters
gp130 (show LRPPRC Antibodies)-mediated adipose tissue lipolysis promotes hepatic steatosis and insulin (show INS Antibodies) resistance.
differences exist in the expression of receptors utilized by the IL-6 (show IL6 Antibodies)/gp130 (show LRPPRC Antibodies) family of cytokines in astrocytes and microglia, and (2) the findings provide a molecular basis for the differential response to oncostatin M (show OSM Antibodies) by astrocytes versus microglia
Deregulation of gp130 (show LRPPRC Antibodies)/STAT3 (show STAT3 Antibodies) signalling augments the acute phase reponse and macrophage infiltration during atherosclerosis without impacting on the development of aortic plaques.
The expression of IL-6, IL-6R and gp130 transcripts were detected very early, increased during the first week of life and were predominantly expressed in the head, epidermis and neuromasts of the anterior and posterior lateral line system.
The protein encoded by this gene is a signal transducer shared by many cytokines, including interleukin 6 (IL6), ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), and oncostatin M (OSM). This protein functions as a part of the cytokine receptor complex. The activation of this protein is dependent upon the binding of cytokines to their receptors. vIL6, a protein related to IL6 and encoded by the Kaposi sarcoma-associated herpesvirus, can bypass the interleukin 6 receptor (IL6R) and directly activate this protein. Knockout studies in mice suggest that this gene plays a critical role in regulating myocyte apoptosis. Alternatively spliced transcript variants encoding distinct isoforms have been described. A related pseudogene has been identified on chromosome 17.
, IL-6 receptor subunit beta
, IL-6R subunit beta
, gp130 of the rheumatoid arthritis antigenic peptide-bearing soluble form
, interleukin receptor beta chain
, interleukin-6 receptor subunit beta
, membrane glycoprotein 130
, membrane glycoprotein gp130
, oncostatin-M receptor subunit alpha
, alanyl aminopeptidase
, aminopeptidase M
, aminopeptidase N
, microsomal aminopeptidase
, interleukin-6 signal transducer
, interleukin 6 signal transducer
, glycoprotein 130
, LOW QUALITY PROTEIN: interleukin-6 receptor subunit beta
, interleukin 6 signal transducer (gp130, oncostatin M receptor)
, interleukin 6 signal transducer receptor